SCL Science Valuation

Is A246960 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A246960 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A246960's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A246960's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A246960?

Key metric: As A246960 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A246960. This is calculated by dividing A246960's market cap by their current revenue.
What is A246960's PS Ratio?
PS Ratio	16.3x
Sales	₩3.77b
Market Cap	₩61.47b

A246960 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	16.5x
Enterprise Value/EBITDA	-29.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A246960's PS Ratio compare to its peers?

The above table shows the PS ratio for A246960 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.9x
A294090 EOFLOWLtd	21.6x	n/a	₩135.7b
A059210 Meta Biomed	0.9x	n/a	₩81.2b
A450330 HASS	3.8x	n/a	₩61.8b
A131030 OPTUS Pharmaceutical	1.1x	n/a	₩87.7b
A246960 SCL Science	16.3x	n/a	₩61.5b

Price-To-Sales vs Peers: A246960 is expensive based on its Price-To-Sales Ratio (16.3x) compared to the peer average (6.9x).

Price to Sales Ratio vs Industry

How does A246960's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
A008490 Suheung	0.2x	6.9%	US$105.85m
A083550 KM	0.3x	n/a	US$24.35m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A246960 is expensive based on its Price-To-Sales Ratio (16.3x) compared to the KR Medical Equipment industry average (2.1x).

Price to Sales Ratio vs Fair Ratio

What is A246960's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A246960 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	16.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A246960's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Access Bio

₩188.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,570.00

2.0%

-37.1%

Vieworks

₩192.8b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,000.00

3.4%

-24.2%

Wonbiogen

₩43.5b

Develops and sells medical equipment in South Korea.

A307280

₩1,225.00

-1.1%

-21.6%